US Stock IR Daily – October 06, 2026 (4 reports)

• Regeneron Pharmaceuticals, Inc. entered into the Sixth Amendment to the Amended and Restated License and Collaboration Agreement with Sanofi Biotechnology SAS and Sanofi.
• Pursuant to this amendment, the parties will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13 antibody.
• Sanofi will make an upfront payment of $1.0 billion to Regeneron.
• Regeneron is entitled to receive up to an additional $7.0 billion in aggregate upon the achievement of certain development, regulatory, and commercial milestones related to the New Licensed Products.
• Global profits realized on the sale of these New Licensed Products will be shared equally between Regeneron and Sanofi.
• All development costs for licensed products, including the New Licensed Products, will be shared equally by the parties; however, development costs exceeding a budget cap for New Licensed Products will be Regeneron’s responsibility.

This agreement suggests Regeneron’s strategy to leverage its innovative antibody pipeline through a significant collaboration. The substantial upfront payment from Sanofi, coupled with potential milestone payments and equal profit sharing, could provide a notable boost to Regeneron’s future revenue streams. This partnership may enable Regeneron to mitigate development risks and costs while expanding the market reach for these new therapeutic candidates.

• NextEra Energy, Inc. announced that on September 22, 2026, the Circuit Court of the 15th Judicial Circuit in and for Palm Beach County, Florida, entered an order setting a hearing in a shareholder derivative action titled “Davidson, et al. v. Silagy, et al.”
• The Settlement Hearing is scheduled for December 14, 2026, at 3:00 p.m. to determine, among other things, whether to approve the terms of a proposed derivative settlement as fair, reasonable, and adequate, and an agreed-upon award of attorneys’ fees and expenses.
• The Court’s Order also directed that notice be given to NextEra Energy Inc.’s shareholders concerning the proposed settlement and their right to be heard at the Settlement Hearing.
• Additional information regarding the proposed settlement, the Settlement Hearing, and objection requirements can be found in the Notice of Pendency and Proposed Settlement of Derivative Actions and the Revised Stipulation and Agreement of Settlement, filed as Exhibits 99.1 and 99.2, respectively, to the Form 8-K.

• On October 6, 2026, Chevron Corporation announced its intent to divest ownership interests in Hess Midstream LP and its DJ Basin crude oil midstream assets.
• Chevron’s preliminary accounting assessment indicates an estimated one-time after-tax loss of approximately $3 billion to $4 billion upon closing, which is expected to be treated as a special item.
• The transaction is subject to specified terms, including customary closing conditions and required regulatory approvals, and is anticipated to close by year-end 2026.

Chevron’s move to divest these midstream assets could indicate a strategic re-evaluation of its portfolio, potentially focusing on core operations or optimizing capital allocation. Investors may want to monitor the implications of the expected after-tax loss as a special item, as well as the long-term impact of this divestment on the company’s operational structure.

• Cintas Corporation reiterated its Agreement and Plan of Merger with UniFirst Corporation, initially entered into on March 10, 2026.
• On October 2, 2026, Cintas and UniFirst certified substantial compliance with the Second Request from the U.S. Federal Trade Commission (FTC).
• Also on October 2, 2026, Cintas and UniFirst entered into a timing agreement with the FTC, agreeing not to consummate the Mergers prior to December 11, 2026, unless written notice of investigation closure is received earlier.
• On September 29, 2026, Cintas and UniFirst certified completion of their response to the Supplementary Information Request (SIR) from the Canadian Competition Bureau (CCB).
• Cintas continues to expect the Mergers to close prior to the end of calendar year 2026.

This announcement provides an update on the regulatory clearance process for Cintas’s acquisition of UniFirst. The timing agreement with the FTC sets a specific benchmark for the earliest potential closing date, offering investors a clearer timeline. The completion of responses to both U.S. and Canadian regulatory bodies suggests progress in addressing antitrust concerns. Cintas’s continued expectation for a calendar year-end closing may indicate confidence in overcoming the remaining conditions.